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Abstract: Prostanoids have a broad spectrum of biological activities in a variety of organs including the brain. However, 
their effects on synaptic plasticity in the brain, which have been recently revealed, are ambiguous in comparison to those 
in the other organs. Prostaglandin E2 (PGE2) is a prostanoid produced from arachidonic acid in the cellular membrane, and 
knowledge about its functions is increasing. Recently, a novel function of PGE2 in the brain has shed light on aspects of 
synaptic plasticity such as long-term potentiation (LTP). More recently, we have proposed a hypothesis for the mechanisms 
of this PGE2-related form of synaptic plasticity in the visual cortex. This involves the dynamics of two subtypes of PGE2 
receptors that have opposing functions in intracellular signal transduction. Consequently, mechanisms that increase the 
level of cyclic AMP in the cytosol may explain for the mechanisms of LTP in the visual cortex. The current notion of bidi-
rectional trafﬁ  cking of PGE2 receptors under this hypothesis is reminiscent of the “silent synapse” mechanism of LTP on 
the trafﬁ  cking of the AMPA receptors between the membrane and cytosol. Moreover, we propose the hypothesis that PGE2 
acts as a “post-to-postsynaptic messenger” for the induction of LTP in the visual cortex. This review describes a complex 
mode of action of PGE2 receptors in synaptic plasticity in the brain.
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Production of PGE2
Prostanoids are classiﬁ  ed into prostaglandins and the thromboxanes. Prostaglandins consist of prosta-
glandin (PG)D2, PGE2, PGF2a, and PGI2, whereas thromboxanes consist of thromboxane A2 (TxA22). 
All of these products are metabolites of arachidonic acid, which originates from the phospholipid 
components of the cell membrane. Arachidonic acid is converted to PGG2 by the cyclooxygenases, 
which comprise cyclooxygenase(COX)-1, -2, and 3 (for review, see Schwab et al. 2003). COX-1 is 
ubiquitous and COX-3 is a splice variant of COX-1, whereas COX-2 is inducible in the brain by the 
activity in the physiological or pathological condition. For example, the level of COX-2 mRNA is 
enhanced in long-term potentiation (LTP), which is a form of synaptic plasticity and is deﬁ  ned as the 
persistent enhancement of synaptic transmission efﬁ  cacy (Yamagata et al. 1993; Chen and Bazan, 2005). 
Because PGG22 is remarkably unstable, PGG2 is immediately converted to PGH2. Then PGH2 is 
metabolized to a speciﬁ  c prostanoid by a corresponding synthase; for example, PGE2 is produced by 
the PGE synthase. 
In the prostanoids, PGG2, PGH2, PGI2 and TxA2 are degraded into inactive products within several 
minutes even under physiological conditions, whereas in in vivo the other prostaglandins are immedi-
ately inactivated through circulation in the lungs, where oxidative stress is strong. It is believed that 
because of the chemical and biological instability of prostanoids, the area, where the activity of 
prostanoids is essential for performing and maintaining the physiological conditions is believed to be 
restricted around the region where they prostanoids are produced. Prostanoids are hydrophobic, because 
they are synthesized from fatty acids in the cell membrane. This property allows them to pass through 
the membrane and reach neighboring cells. Thus, prostanoids are able to exert their functions 
approximately in spite of their short lifetime. This is consistent with the fact that the prostanoids which 
are produced in the brain do not circulate in the blood, and yet can act in the neighboring subcellular 
regions, such as synapses.84
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Receptors for PGE2
Four subtypes of receptor for PGE2 have been 
identiﬁ  ed: EP1, EP2, EP3, and EP4 (EP1-4) (for 
review, see Narumiya et al. 1999; Narumiya and 
FitzGeraldl, 2001). These four receptor subtypes 
are expressed in different levels in the brain as well 
as in the other organs.
Although EP1 mRNA is distributed mainly in 
the kidneys, lungs, and stomach, EP1 is also found 
in the neurons in thalamus and dorsal root ganglia 
(DRG) (Watabe et al. 1993). However, a recent 
study showed that the levels of EP1 mRNA are 
the highest in the parietal cortex and cerebellum 
and that the protein level of EP1 is high in cere-
bellum (Candelario-Jalil et al. 2005). Although 
EP2 is the least abundant among the PGE2 
receptor subtypes in the brain, its expression can 
be induced by stimulation with lipopolysaccha-
ride (LPS) and gonadotropin (Katsuyama et al. 
1998). A study involving Northern blot analysis 
and in situ hybridizatuion showed that EP3 is 
expressed abundantly and widely in the brain 
(Sugimoto et al. 1992). EP3 mRNA is expressed 
in the neurons of the cerebral cortex, hippo-
campus, thalamus, midbrain, and lower brain 
stem. However, EP4 mRNA is expressed only in 
the neurons of the DRG (Sugimoto et al. 1994; 
Oida et al. 1995; Burks et al. 2007).
Binding of agonists to these receptor subtypes 
induces signal transduction via secondary messen-
gers, such as cyclic AMP (cAMP), in a G protein-
coupled manner. The activation of EP1 elevates 
the levels of intracellular inositol phosphate and 
Ca
2+ (Watabe et al. 1993), whereas the activation 
of EP2 or EP4 stimulates adenylate cyclase, 
resulting in increased levels of intracellular cAMP 
(Jumblatt and Paterson, 1991). Conversely, acti-
vation of EP3 inhibits adenylate cyclase (Sugi-
moto et al. 1992). Recently, we have shown that 
synaptic plasticity in the visual cortex is deeply 
involved in these opposing effects of EP2 and 
EP3 on the production of cAMP. This is a good 
way to acquire the sufﬁ  cient cAMP for the induc-
tion of LTP (see below).
Functions of PGE2 in the Brain
PGE2 is a mediator of fever induction (Milton and 
Wendlandt 1970). It acts as a ﬁ  nal mediator in the 
induction of fever by the pyrogens acting on the 
organum vasculosum of the lamina terminalis 
(OVLT) of the third lateral ventricle (Saper and 
Breder, 1994). An in situ hybridization study 
showed that EP3 mRNA is expressed at a 
particularly high level in the regions surrounding 
the OVLT (Sugimoto et al. 1994). Circulating 
pyrogens that may generate PGE2 have an easy 
access to the OVLT because it lacks blood-brain 
barrier. There have been increasing numbers of 
knockout (KO) studies on the four receptor 
subtypes, EP1-4, and in one of these studies EP3-
deﬁ  cient mice showed no febrile responses to any 
of the pyrogens tested (Ushikubi et al. 1998). 
PGE2 and PGI2 promote bradykinin-induced 
pain (Katori et al. 1986). However, a KO study 
on the receptors involved revealed that this type 
of pain may require receptors for PGI2 rather than 
PGE2 (Murata et al. 1997). It is also known that 
PGE2 acts on the spinal dorsal horn to produce 
pain (Malmberg et al. 1995; Pitcher and Henry, 
1999). Outside the central and peripheral nervous 
systems, it is known that PGE2 promotes the 
coagulation of platelets via EP3 (Ma et al. 2001), 
bone resorption and formation (Sakuma et al. 
2000; Miyata et al. 2000; Li et al. 2000), cancer 
and carcinogenesis (Watanabe et al. 1999), hyper-
tension (Kennedy et al. 1999; Tilley et al. 1999) 
and cardiovascular functions (Audoly et al. 1999; 
Zhang et al. 2000). Thus, PGE2 exerts a variety 
of functions in the body, including the brain. 
However, it is only recently that PGE2 has been 
shown to have functions in synaptic plasticity.
Knockdown for EP1-4
It is important to evaluate the functions of known 
and novel genes in order to understand the 
mechanisms involved. Genetic manipulation by 
KO is a useful tool to characterize a target gene. 
Indeed, KO studies in mice for EP1-4 in mice 
KO studies have been reported recently. The most 
eminent feature of genetic manipulation by KO 
is its speciﬁ  city for the target gene, i.e. the genes 
whose expression is to be deduced. This is the 
most important reason why the method has 
become so popular and has produced so much 
information over the last decade. However, gene 
KO has shortcomings that hinder its use in 
ordinary laboratories. These include (1) the 
unpredictable effects of the knocked-out protein 
on other proteins that might in turn inﬂ  uence 
some other proteins especially during develop-
ment. This makes it difﬁ  cult to know whether 
the results obtained are caused because of the 85
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absence of the target protein or other proteins; 
(2) the high frequency of death before birth or 
during early postnatal development, resulting in 
reduced opportunity to conduct experiments; (3) 
the limitation of the knocked-out region (in most 
cases, the whole body). The effect of ordinary 
KO manipulation is systemic and begins at fertil-
ization in almost all cases. It is difﬁ  cult to predict 
the location and timing of the effect of the KO 
desired; (4) the fact that in most cases KO 
experiments are limited to mice, resulting in the 
restriction on the use of antibodies, DNA probes 
and so on; and (5) the large expenditure, labor, 
and time required to establish the KO model. 
With respect to reason (1), it is difﬁ  cult to know 
whether the results obtained are caused by the 
absence of the target protein or by the absence 
or lack of other proteins. With respect to the 
reason (3), the effect of ordinary KO manipula-
tion is systemic and begins at fertilization in 
almost all cases. It is difﬁ  cult to predict exactly 
the location and timing for the effects of the KO 
desired. Nonetheless, KO manipulations have 
been used to analyze the function of the target 
proteins by many researchers. This is mainly 
because of the speciﬁ  city of targeting, which 
presumably avoids none-speciﬁ  c actions, such 
as pharmacological actions.
An alternative way to inhibit the target expression 
is by RNA interference (RNAi), in which stretches 
of 21–23 nucleotides of RNA, termed short (or 
small) interfering RNA (siRNA), are used to inhibit 
the expression of the target mRNA, resulting in the 
inhibition of the target protein (Fire et al. 1998). The 
mechanisms of RNAi is believed to be as follows. 
The enzyme Dicer, a member of the RNase III 
family of nucleases, speciﬁ  cally cleaves double-
stranded RNAs to form siRNAs. The siRNAs 
subsequently bind to RNAi-induced silencing 
protein complex (RISC), which contains an endo-
nuclease; this is followed by targeting the perfectly 
complementary mRNA and cleaving the target 
within the sequences covered by the siRNA. Guid-
ance of RISC to the target mRNA is highly 
sequence-speciﬁ  c; a difference of only one or two 
nucleotides in the targeting recognition sequence 
interferes with the RNAi process. The primary 
siRNA-template RNA can be used to support 
de novo RNA synthesis by an RNA-dependent RNA 
polymerase, resulting in the ampliﬁ  cation of RNA. 
With respect to target speciﬁ  city and the efﬁ  cacy of 
maintenance of RNAi, the method using siRNA has 
great advantages over the use of the conventional 
antisense oligonucleotides to knock down the 
target. 
For introducing exogenous molecules such as 
proteins, RNA, and DNA into the cells, electro-
poration is a convenient and efﬁ  cient method (for 
review, see Neumann et al. 1999). The mechanisms 
comprises two steps: ﬁ  rst, electrical shocks applied 
at the membrane produce pores that last for tens 
of seconds; external molecules that are negatively 
charged then enter the cytosol by electrophoresis. 
The efﬁ  ciency of expression of exogenous genes 
has been reported to be 10–100% according to the 
parameters of electric impulses used. In most cases, 
however, the targets of the in vivo electroporation 
are whole organs, such as the liver and brain in the 
embryonic stages of the chick and mouse. 
Electroporation at the embryonic stage offers the 
possibility of inﬂ  uencing the destiny of the proteins 
other than the target as mentioned above.
To resolve the defects of systemic KO or 
knockdown manipulation mentioned above, we 
developed a novel method, termed RNAi-induced 
silencing by local electroporation, RISLE (Akaneya 
et al. 2005). It involves electroporation with the two 
needle electrodes after injecting siRNA into the 
target area of the brain to introduce the siRNA. In 
a recent paper, we showed that the target gene 
expression at the site where siRNA is injected 
between the two electrodes is exclusively knocked 
down, and that the effect is target-speciﬁ  c. We also 
found that, when using a combination of siRNA 
with local electroporation, the expression of certain 
proteins is signiﬁ  cantly reduced in the restricted 
regions, such as the visual cortex and the CA1 region 
of the hippocampus, and use of the technique does 
not induce pathological changes. Moreover, we have 
shown that this model is available for in vitro and 
in vivo experiments such as electrophysiology.
Using the RISLE method, we knocked down 
EP1-4 in rats and analyzed the mechanisms of 
synaptic plasticity in the visual cortex with these 
knockdown rats (Akaneya and Tsumoto, 2006). 
We found that both EP2 and EP3, but not EP1 or 
EP4, are involved in the LTP in the visual cortex.
Differences in Site of Action 
of PGE2 between Hippocampus 
and Visual Cortex
Previous papers have reported the effect of PGE2 
on synaptic plasticity. However, there is controversy 86
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regarding the sites of action of PGE2, i.e. 
presynaptic or postsynaptic sites of neurons. First, 
it has been reported that PGE2 increases excitatory 
postsynaptic potentials (EPSPs) in hippocampal 
slices and frequency, and that this action is via the 
EP2 which is located at the presynaptic sites (Sang 
et al. 2005; Zhu et al. 2005). This suggests the 
presynaptic action of PGE2. Immediately after this 
publication, we showed that PGE2 increases the 
magnitude of theta-burst stimulation (TBS; 5 
stimulus trains at the interval of 10s, each train 
consisting of 10 bursts at 5 Hz and each burst 
consisting of 4 pulses at 100 Hz) induced LTP in 
the slices of rat visual cortex. Glutamate released 
from presynaptic sites by TBS activates N-methyl-
D-aspartate receptor (NMDAR) at postsynaptic 
sites, followed by a Ca
2+ inﬂ  ux. This activates 
Ca
2+-dependent cPLA2, which then produces arachi-
donic acid from the membrane lipid substrate, in 
addition to the activation of Ca
2+/calmudulin-
dependent protein kinase II (CaMKII). Arachidonic 
acid is metabolized to PGH2 by COX-2 that has 
been activated by TBS concomitantly (Akaneya 
and Tsumoto, 2006). This action is mediated via 
EP2 at the postsynaptic sites in neurons of the 
visual cortex, which is inconsistent with the 
previous study in the hippocampus. The two 
studies depend mainly on the electrophysiological 
approach and the immunocytochemical analysis 
of the pre- and postsynaptic marker proteins, 
synaptophysin and postsynaptic density protein-95 
(PSD-95), respectively. PGE2 increased the 
synaptic stimulus-evoked amplitudes of EPSPs in 
hippocampal slices and the frequency of miniature 
excitatory postsynaptic currents (mEPSCs) in 
hippocampal neurons in culture (Sang et al. 2005). 
In contrast, PGE2 has no signiﬁ  cant effects on the 
paired-pulse ratio in the visual cortex slices or on 
the release of glutamate from synaptoneurosomes 
of the visual cortex (Akaneya and Tsumoto, 2006). 
Immunocytochemical analysis of the hippocampal 
neurons in culture revealed that EP2 highly 
colocalized with synaptophysin (71.0%), but 
partially with PSD-95 (14.2%), whereas EP3 
partially colocalized with PSD-95 (45.3%) or 
synaptophysin (38.7%) (Zhu et al. 2005). The 
former and the other results suggest the pre- and 
postsynaptic actions of PGE2, respectively. 
In cultures of neurons from the visual cortex, 
however, both EP2 and EP3 are highly colocalized 
with PSD-95 (EP2, 71%; EP3, 82%), but less 
colocalized with synaptophysin (EP2, 25%; 
EP3, 13%) (Akaneya and Tsumoto, 2006). The 
difference may be due to the subcellular location 
of EP2, i.e. at the presynaptic site in the hippo-
campus and at the postsynaptic site in visual cortex. 
Moreover, both studies showed that EP2 and EP3, 
but not EP1 or EP4, are abundantly expressed in 
the hippocampus or visual cortex. This suggests 
the implication of EP2 and EP3 in the physiological 
functions of these regions of the brain. Another 
common point between these two studies is that 
PGE2 is synthesized at the postsynaptic sites by 
COX-2. Other papers have reported various 
ﬁ  ndings about neuronal and synaptic functions 
which are common to the hippocampus and visual 
cortex. Further investigation, such as electron 
microscopic studies of the subcellular distribution 
of EP receptor subtypes, especially for EP2, is 
necessary in order to resolve this inconsistency.
A Hypothesis: Bidirectional Trafﬁ  cking 
of PGE2 Receptor Subtypes
LTP comprises early- and late-LTP (E-LTP and 
L-LTP, respectively) (Frey et al. 1993; Abel et al. 
1997; Huang et al. 2004). E-LTP lasts for a few 
hours after its initiation, and L-LTP lasts for hours, 
days or even months after the end of E-LTP. As 
mentioned above, we have shown that PGE2 
increases the magnitude of both E- and L-LTP in 
the visual cortex (Akaneya and Tsumoto, 2006). 
This involves interesting and efﬁ  cient trafﬁ  cking 
of EP2 and EP3, both of which are located at the 
postsynaptic sites in the neurons of the visual 
cortex. We propose the following to account for 
the mechanism of PGE2-related LTP. In the 
stationary state, EP2 and EP3 are mainly located 
in the cytosol and at the membrane, respectively 
(Fig. 1). The TBS that induces LTP causes 
bidirectional trafﬁ  cking of EP2 and EP3 into the 
membrane and the cytosol, respectively, which 
results in an increase in EP2 and a decrease in EP3 
at the membrane. Simultaneously, TBS produces 
PGE2 by COX-2. PGE2-stimulation of EP2 or EP3 
induces an increase or a decrease in the level of 
cAMP, respectively, in the cytosol via adenyl 
cyclase (Jumblatt and Paterson, 1991; Sugimoto 
et al. 1992). This shift in the composition of the 
PGE2 receptor subtypes at the membrane, i.e. the 
predominant location of EP2, can easily induce 
the production of a large amount of cAMP in 
the cytosol. Consequently, cAMP activates 
cAMP-dependent protein kinase (PKA), which 87
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may in turn activate cAMP response element 
binding protein (CREB), a transcription factor, in 
the nucleus. The maintenance of L-LTP depends 
on protein synthesis (Frey et al. 1993; Abel et al. 
1997; Huang et al. 2004). This new protein 
synthesis resulting from the activation of CREB 
may therefore be involved in L-LTP. It is known 
that synaptogenesis occurs during L-LTP, and 
these newly synthesized proteins may be used for 
the formation of synapses. 
A pharmacological analysis revealed that 
CaMKII may be involved in the trafﬁ  cking of EP2 
from the cytosol to the membrane, but the mecha-
nism of EP3-trafﬁ  cking is unknown (Akaneya and 
Tsumoto, 2006). The dynamic force causing this 
trafﬁ  cking might be provided by as yet unknown 
EP2- and EP3-interacting proteins, similar to the 
AMPA receptor-interacting proteins involved in 
the so-called silent synapse mechanisms (Harris 
and Lim, 2001; Barry and Ziff, 2002; Collingridge 
et al. 2004). This bidirectional trafﬁ  cking of EP2 
and EP3 is similar to the trafﬁ  cking of AMPA 
receptors in LTP.
A candidate for the product formed as a conse-
quence of the activation of CREB is brain-derived 
neurotrophic factor (BDNF). Our previous work 
has shown that BDNF increases the efﬁ  cacy of 
synaptic transmission and TBS-induced LTP in the 
2
Figure 1. Hypothetical mechanism of PGE2-mediated LTP in the visual cortex. TBS produces arachidonic acid (AA) from the membrane 
lipid substrate. AA is metabolized to PGH2 by COX-2 that has been activated concomitantly by TBS. PGH2 is converted immediately to PGE2 
by PGE2 synthase. EP2 translocates from the cytosol to the membrane, simultaneously, with the translocation of EP3 from the membrane 
to the cytosol. The PGE2 that is generated spreads from postsynaptic sites into the synaptic cleft, where it activates EP2 at the postsynap-
tic membrane, resulting in the production of cAMP. Subsequently, cAMP activates PKA, which in turn activates CREB in the nucleus of 
postsynaptic cells in the visual cortex. This activation of CREB may induce the synthesis of proteins such as BDNF, which is involved in the 
L-LTP.88
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visual cortex (Akaneya et al. 1997). Moreover, 
quantitative PCR analysis has shown that TBS 
induces the generation of BDNF mRNA in the 
visual cortex (Akaneya and Tsumoto, 2006). 
Taking these results together, we surmise that PGE2 
has a direct action on E-LTP and an indirect action 
on L-LTP via the production of BDNF.
A Hypothesis: A Candidate 
for “Post-to-Postsynaptic Messenger”
The induction of LTP requires the activation 
of NMDA receptor at the postsynaptic cells. The 
maintenance of LTP requires, at least in part, a 
change in presynaptic function. In other words, 
some known or unknown factors, the so-called 
retrograde messengers, must be transmitted from 
the postsynaptic to the presynaptic cells, where 
they must affect presynaptic functions. Many 
candidates for these retrograde messengers have 
been proposed (for review, see Williams, 1996). It 
is possible to say that in the hippocampus PGE2 
works as a retrograde messenger, because PGE2 is 
produced at the postsynaptic site and then diffuses 
across the postsynaptic membrane to the presynaptic 
site where EP2 is distributed (Chen et al. 2005; 
Sang et al. 2005; Zhu et al. 2005). In the visual 
cortex, on the other hand, it is possible to say that, 
as a new conception, PGE2 works as a “post-
to-postsynaptic messenger,” because PGE2 is 
produced at the postsynaptic site and then passes 
across the membrane into the synaptic cleft where 
PGE2 activates EP2 at the postsynaptic membrane 
(Akaneya and Tsumoto, 2006).
Conclusion
PGE2 is generated from membrane phospholipids, 
which is ubiquitous in the central nervous systems. 
The prostanoids that is produced from this source 
is not only PGE2. Therefore, it is important to 
regulate the production of PGE2 for the maintenance 
and successful accomplishment of function. Here 
I want to propose “an intricate machinery” of 
neurons to yield the energy that is necessary for 
ordinary synaptic functions. Bidirectional traf-
ﬁ  cking of the two subtypes, EP2 and EP3, which 
have reciprocal actions is one of the ways by which 
synaptic functions may be regulated. In future, 
further elucidation of the mechanisms of action of 
PGE2 in the synaptic plasticity, in combination with 
new methods for introducing agents into the 
restricted brain regions, such as RISLE, may come 
to be useful for developing new therapies for 
psychoneurological diseases such as dementia and 
cerebrovascular diseases. 
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